Additional file 1: of Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Sensitivity analysis of the risk of CID events for common visits, characterization of patients according to CID endpoints achieved and analysis of the risk of CID events over 24 weeks, stratified by ICS use, previous treatment, and symptoms. (DOCX 289 kb)